Singapore, April 10, 2008:  Dabur Pharma, India’s leading oncology player has recently signed an agreement with Government Pharmaceutical Organization (GPO) of Thailand for generic version of one of its key anticancer products.

 

Mr Ajay Kumar Vij, CEO Dabur Pharma, said “Dabur Pharma is committed to providing high quality anticancer products at cost effective prices. The agreement with GPO has been signed for generic Docetaxel Injection at a very special price. GPO will be importing the product in Thailand and then making it available to needy patients. This agreement is to support the efforts of the Health Minister of Thailand to provide universal access to essential medicines for patients with low income by way of Compulsory Licensing.”

 

Dabur Pharma is a key player in the field of oncology and is among the top generic oncology companies in various markets, including in Thailand, Philippines, Malaysia and India. Besides presence in more than 40 countries, it has strong presence in the US with substantial market shares for Paclitaxel Injection and Irinotecan Injection.